In short
Clinical trials for Zinc Oxide are not shown in the source data provided here. The trial records available instead study dapirolizumab pegol in people with systemic lupus erythematosus, with goals such as long-term safety and treatment response. These studies focus on adults with moderately to severely active SLE.
Key points
- The provided trial data does not include any studies of Zinc Oxide. Instead, it describes two Phase 3 studies of dapirolizumab pegol in people with systemic lupus erythematosus (SLE). One trial looks at whether the treatment helps people with moderately to severely active SLE reach a clinical response by Week 48. The other trial studies long-term safety and tolerability, including treatment-emergent adverse events and serious adverse events. Both are interventional studies in people with SLE. The target population is adults with this autoimmune disease.
Trial overview
The source data provided for this article does not include any clinical trials of Zinc Oxide. Instead, it includes two studies of dapirolizumab pegol in people with systemic lupus erythematosus (SLE).
Both studies are marked Authorised and both are Phase 3 interventional trials, which means they are later-stage studies that test treatment effects in people.
Condition studied
The condition studied in both trials is systemic lupus erythematosus, a long-term disease in which the immune system attacks the body's own tissues.
One trial focuses on people with moderately to severely active disease, meaning the lupus activity is at a noticeable or serious level.
The second trial looks at people with SLE more broadly and is designed to study long-term safety and tolerability.
Trial design and phase
Both studies are interventional, so participants receive a study treatment and the results are measured over time.
The first trial has an enrollment of 459 people, and the second trial has an enrollment of 765 people.
The first study evaluates dapirolizumab pegol as an add-on to standard of care, which means the usual treatment people already receive.
The second study also includes dapirolizumab pegol and measures long-term safety outcomes during the study.
Main outcomes being measured
The first study's main outcome is BICLA response at Week 48, which is a lupus disease activity measure used to see whether the disease has improved.
The second study focuses on safety outcomes, including the incidence of treatment-emergent adverse events, serious treatment-emergent adverse events, and adverse events that lead to permanent discontinuation of dapirolizumab pegol.
In simple terms, the researchers are checking both whether treatment helps and whether people can use it safely over time.
Who the studies are for
The target population in both records is people with systemic lupus erythematosus.
One study is aimed at people with moderately to severely active SLE, while the other is aimed at people with SLE who are being followed for longer-term safety.
What this means for readers
Based on the source data, there are no trial records here for Zinc Oxide.
The available records are still useful because they show how clinical trials are described: by condition, phase, enrollment, design, and the main outcomes being measured.